Anderson WF - Search Results

1

Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors.

Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL. Masood R, et al. Among authors: anderson wf. Int J Mol Med. 2001 Oct;8(4):335-43. doi: 10.3892/ijmm.8.4.335. Int J Mol Med. 2001. PMID: 11562769

2

Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein.

Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA, Anderson WF. Hall FL, et al. Among authors: anderson wf. Hum Gene Ther. 1997 Dec 10;8(18):2183-92. doi: 10.1089/hum.1997.8.18-2183. Hum Gene Ther. 1997. PMID: 9449372

3

Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide.

Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM. Wu BW, et al. Among authors: anderson wf. Virology. 2000 Mar 30;269(1):7-17. doi: 10.1006/viro.2000.0201. Virology. 2000. PMID: 10725193 Free article.

4

Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells.

Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. Liu L, et al. Among authors: anderson wf. J Virol. 2000 Jun;74(11):5320-8. doi: 10.1128/jvi.74.11.5320-5328.2000. J Virol. 2000. PMID: 10799609 Free PMC article.

5

Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor.

Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW, Gordon EM. Hall FL, et al. Among authors: anderson wf. Hum Gene Ther. 2000 May 1;11(7):983-93. doi: 10.1089/10430340050015293. Hum Gene Ther. 2000. PMID: 10811227

6

Lesion-targeted injectable vectors for vascular restenosis.

Gordon EM, Zhu NL, Forney Prescott M, Chen ZH, Anderson WF, Hall FL. Gordon EM, et al. Among authors: anderson wf. Hum Gene Ther. 2001 Jul 1;12(10):1277-87. doi: 10.1089/104303401750270931. Hum Gene Ther. 2001. PMID: 11440621

7

Gene therapy using retroviral vectors.

Gordon EM, Anderson WF. Gordon EM, et al. Among authors: anderson wf. Curr Opin Biotechnol. 1994 Dec;5(6):611-6. doi: 10.1016/0958-1669(94)90083-3. Curr Opin Biotechnol. 1994. PMID: 7765744 Review.

8

Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze.

Behrens A, Gordon EM, Li L, Liu PX, Chen Z, Peng H, La Bree L, Anderson WF, Hall FL, McDonnell PJ. Behrens A, et al. Among authors: anderson wf. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):968-77. Invest Ophthalmol Vis Sci. 2002. PMID: 11923236

9

Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver.

Lenz HJ, Anderson WF, Hall FL, Gordon EM. Lenz HJ, et al. Among authors: anderson wf. Hum Gene Ther. 2002 Aug 10;13(12):1515-37. doi: 10.1089/10430340260185148. Hum Gene Ther. 2002. PMID: 12215272 No abstract available.

10

Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.

Song JC, McDonnell PJ, Gordon EM, Hall FL, Anderson WF. Song JC, et al. Among authors: anderson wf. Hum Gene Ther. 2003 Feb 10;14(3):306-9. Hum Gene Ther. 2003. PMID: 12675032 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

753 results

Search Page

Filters